Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Cash & Equivalents (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Cash & Equivalents for 6 consecutive years, with $34.3 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 48.5% to $34.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $34.3 million through Dec 2025, down 48.5% year-over-year, with the annual reading at $34.3 million for FY2025, 48.5% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $34.3 million at Lexicon Pharmaceuticals, down from $49.7 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $102.3 million in Q2 2023, with the low at $21.1 million in Q3 2023.
  • Average Cash & Equivalents over 3 years is $47.8 million, with a median of $35.1 million recorded in 2024.
  • Peak annual rise in Cash & Equivalents hit 271.12% in 2024, while the deepest fall reached 65.17% in 2024.
  • Over 3 years, Cash & Equivalents stood at $22.5 million in 2023, then soared by 196.71% to $66.7 million in 2024, then tumbled by 48.5% to $34.3 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $34.3 million, $49.7 million, and $21.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.